VistaGen Therapeutics, Inc.(VTGN)

$0.24—

Chart

VistaGen Therapeutics, Inc.(VTGN)

NASDAQ

$0.24—

Chart Studio

VTGN(VTGN)

VTGN

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.38

Nov 12, 2026

Revenue Estimate

$500,000

Analyst Sentiment

Wall St. Consensus

Hold

7 analysts·Limited coverage

Score

3 Buy (43%)4 Hold (57%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

343%

Hold

457%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$0.90

+268.9%

Consensus

$0.95

+289.3%

Bull

$1.00

+309.8%

12-Month Target Range7 analysts

$0.90$0.95$1.00

Current $0.24Consensus

Current Price

$0.24

Upside to Consensus

$0.71

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+63.35%

EPS—

FY2028

Rev+314.69%

EPS—

FY2029

Rev+185.71%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$7M	$20M	$80M
Low	$2M	$7M	$20M	$80M
High	$2M	$7M	$20M	$80M
EBITDA Avg	$-1M	$-4M	$-12M	$-48M
Low	$-1M	$-4M	$-12M	$-48M
High	$-1M	$-4M	$-12M	$-48M
EBIT Avg	$-1M	$-4M	$-12M	$-48M
Low	$-1M	$-4M	$-12M	$-48M
High	$-1M	$-4M	$-12M	$-48M
Net Income Avg	$-62M	$-59M	$-63M	$-21M
Low	$-62M	$-59M	$-63M	$-21M
High	$-51M	$-59M	$-63M	$-21M
EPS Avg	$-1.48	$-1.54	$-1.66	$-0.56
Low	$-1.62	$-1.54	$-1.66	$-0.56
High	$-1.33	$-1.54	$-1.66	$-0.56
Analysts (Rev / EPS)	2 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028
Revenue Avg	$500,000	$500,000	$500,000	$906,546	$802,539	$710,464	$628,953
Low	$500,000	$500,000	$500,000	$906,546	$802,539	$710,464	$628,953
High	$500,000	$500,000	$500,000	$906,546	$802,539	$710,464	$628,953
EBITDA Avg	$-300,000	$-300,000	$-300,000	$-543,927	$-481,523	$-426,278	$-377,371
Low	$-300,000	$-300,000	$-300,000	$-543,927	$-481,523	$-426,278	$-377,371
High	$-300,000	$-300,000	$-300,000	$-543,927	$-481,523	$-426,278	$-377,371
EBIT Avg	$-300,000	$-300,000	$-300,000	$-543,927	$-481,523	$-426,278	$-377,371
Low	$-300,000	$-300,000	$-300,000	$-543,927	$-481,523	$-426,278	$-377,371
High	$-300,000	$-300,000	$-300,000	$-543,927	$-481,523	$-426,278	$-377,371
Net Income Avg	$-16M	$-16M	$-15M	$-1M	$-9M	$-18M	$-36M
Low	$-19M	$-17M	$-15M	$-1M	$-9M	$-18M	$-36M
High	$-14M	$-15M	$-15M	$-1M	$-9M	$-18M	$-36M
EPS Avg	$-0.38	$-0.36	$-0.36	$-0.03	$-0.21	$-0.41	$-0.84
Low	$-0.43	$-0.39	$-0.36	$-0.03	$-0.21	$-0.41	$-0.84
High	$-0.32	$-0.34	$-0.36	$-0.03	$-0.21	$-0.41	$-0.84
Analysts (Rev / EPS)	3 / 1	3 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Dec 17, 2025Jefferies

Jefferies Downgrades VistaGen Therapeutics (VTGN) to Hold

Target:$0.90

+5.1%from $0.86

Dec 17, 2025Stifel Nicolaus

Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints

Target:$1.00

+26.1%from $0.79

Nov 17, 2025Stifel Nicolaus

Stifel Reiterates Buy Rating on VistaGen Therapeutics (VTGN)

Target:$12.00

+161.2%from $4.59

Jul 22, 2022Jefferies

VistaGen Therapeutics downgraded to Hold from Buy at Jefferies

Target:$0.20

-95.4%from $4.38

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance